Amgen's Q3 2016 earnings call presented several key points that suggest a positive short-term outlook for the company's stock:

1. **Strong Financial Performance**: Amgen reported a 2% increase in revenues to $5.8 billion, with non-GAAP operating income growing 9% and non-GAAP EPS increasing 11% year-over-year. This indicates robust financial health and operating leverage[5].

2. **Product Performance**: The company saw strong volume growth in several key products, including Prolia, XGEVA, Sensipar, Vectibix, and Nplate. KYPROLIS and REPATHA also showed promising growth, despite some challenges in market access[5].

3. **Pipeline Advancements**: Amgen highlighted significant progress in its pipeline, including positive results from the REPATHA GLAGOV study, advancements in the omecamtiv mecarbil Phase III trial, and the approval of AMJEVITA, their biosimilar to adalimumab. These developments suggest a strong future growth trajectory[5].

4. **Value-Based Contracts**: The company is actively engaging in value-based contracts, which could improve patient access to innovative medicines and provide a more stable revenue stream in a competitive environment[5].

5. **Guidance Update**: Amgen increased its 2016 guidance for revenues and non-GAAP EPS, reflecting continued confidence in their business strategy and performance[5].

Given these points, the stock is likely to experience a positive impact in the short term due to the company's strong financial performance, promising product pipeline, and strategic initiatives.

**[1]**